Steven Cohen Ultragenyx Pharmaceutical Inc. Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 539,749 shares of RARE stock, worth $29.4 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
539,749
Previous 539,749
-0.0%
Holding current value
$29.4 Million
Previous $22.2 Million
-0.0%
% of portfolio
0.06%
Previous 0.06%
Shares
26 transactions
Others Institutions Holding RARE
# of Institutions
287Shares Held
88.1MCall Options Held
505KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA9.78MShares$532 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$305 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.35MShares$291 Million0.68% of portfolio
-
Wellington Management Group LLP Boston, MA4.56MShares$248 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY3.26MShares$177 Million2.24% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.81B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...